Replies to post #172832 on Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

always good to have your accurate DD, Daupers. Thanks.

Longs - Please keep this in mind. A little reality check :)

Just after the MAKO piece and all the other BS:

July 17th 2015 - $3.36 - SHARE PRICE
August 2015 OS - 118,170,536
Cash - $8.4 Million
Sept 30th 2015 - Still had 28.2 Million from Aspire

Proprietary Program
Indication
Clinical Status
1.
Kevetrin
Inhibitor for Solid Tumors (ONGOING)
Phase 1
2.
Prurisol
Psoriasis
Phase 2A (ONGOING)
3.
Brilacidin
ABSSSI
Phase 2 Completed
4.
Brilacidin - OM
Oral Mucositis
Phase 2 (ONGOING - Just started)



FAST FORWARD ------------------->


February 2017 - Share Price - .93 CENTS
January 2017 OS - 126,408,756
CASH - 3.9 Million
Dec 31st 2016 - Still had 19 million from Aspire

Proprietary Program
Indication
Clinical Status
1.
Kevetrin
Ovarian Phase 2A Trial Recruiting - 10 Patients 2 Cohorts (5 in each)
3X's a week dosing starting at 250mg/m2 compared to Phase 1 which started at 10mg/m2 once a week. THIS COULD BE HUGE!!!
2.
Prurisol
Psoriasis
Phase 2B - Recruiting - 189 Patients; Double the dose from the successful 200mg Phase 2A
Powered Study - Using same scale as most competitors (PASI) and dosing Moderate to Severe - Much more likely to succeed. THIS COULD BE HUGE!!!
3.
Brilacidin
ABSSSI
Phase 3 - SPA on hold until share price rebounds (Partner at anytime)
4.
Brilacidin - OM
Oral Mucositis
Phase 2 - Ongoing - Interim Data due out in 5-7 weeks. THIS COULD BE HUGE!!!
5.
Brilacidin - UP/UC
Currently in 2nd Cohort of 3 Cohorts. Data expected on 2nd Cohort in 1 week. So far excellent Data. THIS COULD BE HUGE!!! If again successful this could show that B-OM is on track to be a winner!



SUMMARY ------>
Down about 4.5 Million in cash - Diluted about 8 Million in OS, but ALL trials are on track to succeed and we have actually moved forward on all fronts. We added huge names to the companies MGMT team and have added several CDA's with BP.

I don't see how anyone in their right mind could justify the market value of CTIX compared to where it was and prior. We are days/weeks/months away from our first major partnership. Hold tight my friends and add willingly.

[DaubersUP]

Recap - In the past 1.5 years, CTIX has Completed:
1) Phase 1 Kevetrin trial at Dana Farber - SUCCESSFUL
2) Phase 2a Prurisol for Mild-Moderate psoriasis - SUCCESSFUL

CTIX began these trials:
1) Phase 2 trial for Brilacidin-OM (Summer 2015) (Interim Data - 5-7 weeks away)
2) Phase 2 Kevetrin for Ovarian Cancer (Winter 2017) (Data this year)
3) Phase 2b Prurisol for Moderate-Severe psoriasis (Fall 2017) (Data this summer)
4) Phase 2 PoC Brilacidin for UP/UC (Summer 2016) (Data on cohort B next week)

Management Additions:
President/CMO - Arthur P. Bertolino
VP, Clinical Sciences and Portfolio Management - Jane Harness
VP Regulatory Affairs - Lavonne Lang

Noteworthy:
*Development of Kevetrin into an Oral drug - so far so good! Bridge study under way.
*In December 2016 management reviewed Cellceutix’s development of Prurisol (KM133) and determined that no royalties on its sales would be due to outside parties.
*Brilacidin Phase 3 for Absssi -  "Our strategy for now is to achieve success with other trials and attract partnering opportunities with significant down payments and milestone payments which can fund these trials."
___________________________

I am probably missing some items but again, within this past 1.5 years and all of the above progress, CTIX has only diluted 8 million shares and have decreased it's cash by 4 million dollars. And the share price in the time has gone from mid $3.00's to just under a $1.
Essentially the science has proved to be everything MGMT has been touting for years. They added very reputable senior management, and have done so by being extremely frugal...
Not to mention they have about 20 million left with Aspire if needed and a 75million shelf-reg.

CTIX will catch up and be back north of $5 soon IMO. We just need to ride the right wave.

[DaubersUP]

B-OM phase 2 started over a year and a half ago - approaching 2 years early this summer. CTIX was very hopeful this trial would show certain properties during the trial that would lead to CTIX starting the B UP trial. Leo hinted many times that this UP trial would only commence if certain feedback from the OM trial was received. Shareholders were pleased to learn the UP trial would commence. Shareholders were then given the first cohort/lowest dose update on B-UP and the results were fascinating according to the staff and comments from the patients were forth telling. The hospital staff even believed the next two cohorts would fill quickly based on word of mouth of this drugs potential. It will be great to hear if cohort 2 follows suite.

I would not be surprised if this cohort 2 has better response and then in a couple weeks OM results prove to be the same. (Same properties are being explored). This could potentially be the first partnership drug. We know B has been followed for years by big Pharm and we know they have agreements where big pharm placed a SECOND large order of B to test the same properties on devices.

Can The OM trial be cut short and could the FDA move it straight to market based on the safety profile and ease of use as a rinse and spit? Does the designation for OM allow that?